Accuray and the University of Wisconsin-Madison Announce Memorandum of Understanding to Advance Online Adaptive Radiotherapy in Support of Improving Cancer Patient Care
Accuray (NASDAQ: ARAY) and the University of Wisconsin School of Medicine and Public Health have signed a memorandum of understanding to advance online adaptive radiotherapy (OART) on Accuray's helical radiation treatment platform. The collaboration will focus on clinical research, education and training, and adaptive technology development to enhance cancer care personalization and precision.
The partnership is particularly significant as UW-Madison researchers were the original inventors of the TomoTherapy® System, the first helical radiation delivery platform. The system revolutionized radiation medicine by enabling integrated 3D daily image-guidance with intensity-modulated radiation therapy (IG-IMRT). The collaboration aims to make OART more accessible to clinical departments of all sizes while advancing the technology's capabilities.
Accuray (NASDAQ: ARAY) e la University of Wisconsin School of Medicine and Public Health hanno firmato un memorandum of understanding per promuovere la radioterapia adattiva online (OART) sulla piattaforma di trattamento radiante elicoidale di Accuray. La collaborazione si concentrerà su ricerca clinica, istruzione e formazione, e sviluppo della tecnologia adattativa per migliorare la personalizzazione e la precisione delle cure oncologiche.
La partnership è particolarmente significativa poiché i ricercatori dell'UW–Madison sono stati i primi a inventare il TomoTherapy® System, la prima piattaforma di erogazione radioterapica elicoidale. Il sistema ha rivoluzionato la medicina radioterapica consentendo una guida-immediata tridimensionale integrata con radioterapia ad intensità modulata (IG-IMRT). La collaborazione mira a rendere l'OART più accessibile ai dipartimenti clinici di tutte le dimensioni, al contempo avanzando le capacità della tecnologia.
Accuray (NASDAQ: ARAY) y la Universidad de Wisconsin, Escuela de Medicina y Salud Pública han firmado un memorando de entendimiento para avanzar la radioterapia adaptativa en línea (OART) en la plataforma de tratamiento de radiación helicoidal de Accuray. La colaboración se centrará en investigación clínica, educación y formación, y desarrollo de tecnología adaptativa para mejorar la personalización y la precisión de la atención oncológica.
La asociación es particularmente significativa ya que los investigadores de UW–Madison fueron los inventores originales del sistema TomoTherapy®, la primera plataforma de entrega de radiación helicoidal. El sistema revolucionó la medicina de la radiación al permitir una guía de imágenes 3D diaria integrada con radioterapia de intensidad modulada (IG-IMRT). La colaboración busca hacer que la OART sea más accesible para departamentos clínicos de todos los tamaños, al tiempo que avanza las capacidades de la tecnología.
Accuray(나스닥: ARAY)와 위스콘신 대학교 의과대학 및 공중보건대학은 Accuray의 헬리컬 방사선 치료 플랫폼에서 온라인 적응형 방사선치료(OART)를 발전시키기 위한 양해각서를 체결했다.
협력은 임상 연구, 교육 및 훈련, 및 적응 기술 개발에 집중하여 암 치료의 개인화 및 정밀성을 향상시키는 것을 목표로 한다.
이 파트너십은 UW–매디슨 연구진이 TomoTherapy® 시스템의 원래 발명가로서 최초의 헬리컬 방사선 전달 플랫폼을 개발했다는 점에서 특히 중요하다. 이 시스템은 IG-IMRT(강도모듈화 방사선치료)와 함께 매일 3D 영상 가이던스가 통합된 형태로 방사선의학을 혁신했다. 협력의 목표는 모든 규모의 임상 부서에서 OART를 보다 쉽게 이용할 수 있도록 하면서 기술의 역량을 발전시키는 것이다.
Accuray (NASDAQ : ARAY) et l'École de médecine et de santé publique de l’Université du Wisconsin ont signé un protocole d’entente pour faire progresser la radiothérapie adaptative en ligne (OART) sur la plateforme de traitement radiologique hélicoïdal d’Accuray. La collaboration se concentrera sur la recherche clinique, l’éducation et la formation, et le développement de technologies adaptatives afin d’améliorer la personnalisation et la précision des soins anticancéreux.
Le partenariat revêt une importance particulière car les chercheurs de UW–Madison ont été les inventeurs initiaux du Tom oTherapy® System, la première plateforme de délivrance de radiations hélicoïdales. Le système a révolutionné la médecine radiothérapeutique en permettant une guidage d’images 3D quotidiennes intégré à la radiothérapie par modulation d’intensité (IG-IMRT). La collaboration vise à rendre l’OART plus accessible aux départements cliniques de toutes les tailles tout en améliorant les capacités de la technologie.
Accuray (NASDAQ: ARAY) und die University of Wisconsin School of Medicine and Public Health haben eine Absichtserklärung unterzeichnet, um die Online Adaptive Radiotherapy (OART) auf Accurays helicaler Strahlentherapieplattform voranzubringen. Die Zusammenarbeit wird sich auf klinische Forschung, Bildung und Schulung sowie die Entwicklung adaptiver Technologien konzentrieren, um die Personalisierung und Präzision der Krebsbehandlung zu verbessern.
Die Partnerschaft ist besonders bedeutsam, da UW–Madison-Forscher die ursprünglichen Erfinder des TomoTherapy®-Systems waren, der ersten helicalen Strahlenausgabplattform. Das System revolutionierte die Strahlenmedizin, indem es eine integrierte 3D-tägliche Bildführung mit intensitätsmodulierter Strahlentherapie (IG-IMRT) ermöglichte. Die Zusammenarbeit zielt darauf ab, OART für klinische Abteilungen jeder Größe zugänglicher zu machen und gleichzeitig die Fähigkeiten der Technologie voranzutreiben.
Accuray (ناسداك: ARAY) و الجامعة الأمريكية للويسكونسن كلية الطب والصحة العامة وقعتا مذكرة تفاهم لتعزيز العلاج الإشعاعي التكيفي عبر الإنترنت (OART) على منصة العلاج الإشعاعي الحلزوني من Accuray. ستركّز الشراكة على البحث السريري والتعليم والتدريب وتطوير التكنولوجيا التكيفية لتحسين تخصيص الرعاية في سرطان ودقتها.
تكتسب الشراكة أهمية خاصة لأن باحثي UW–Madison كانوا المخترعين الأصليين لـ نظام TomoTherapy®، أول منصة توصيل إشعاعي حلزوني. أحدث النظام ثورة في طب الإشعاع من خلال تمكين التوجيه بالإشعاع ثلاثي الأبعاد اليومي المتكامل مع العلاج الإشعاعي بتعديل الشدة (IG-IMRT). وتهدف الشراكة إلى جعل OART أكثر وصولاً إلى الأقسام الإكلينيكية بمختلف أحجامها مع تعزيز قدرات التقنية.
Accuray（纳斯达克：ARAY） 与 威斯康星大学医学院及公共卫生学院 签署了一份谅解备忘录，在 Accuray 的螺旋放射治疗平台上推进在线自适应放疗（OART）。该合作将聚焦于 临床研究、教育与培训，以及自适应技术开发，以提升癌症治疗的个性化与精准度。
此伙伴关系尤为重要，因为 UW–Madison 的研究人员是 TomoTherapy® 系统 的原始发明者，该系统是首个螺旋放射治疗传递平台。该系统通过实现每日的集成三维成像引导与强度调制放射治疗（IG-IMRT）而彻底改变了放射治疗学。合作旨在让 OART 对各种规模的临床科室更易获取，同时推动该技术的能力发展。
- Strategic partnership with the original inventors of TomoTherapy® System
- Potential advancement in personalized cancer treatment technology
- Access to UW-Madison's research expertise and facilities
- No immediate revenue impact disclosed
- Collaboration still in early MOU stage with execution risks
- Timeline for technology development and implementation not specified
Insights
Accuray partners with UW-Madison to develop adaptive radiotherapy technology, leveraging their historical connection to advance precision cancer treatment.
Accuray has signed a memorandum of understanding (MOU) with the University of Wisconsin-Madison to advance online adaptive radiotherapy (OART) on Accuray's helical radiation treatment platform. This collaboration is particularly significant given the historical connection between these organizations - UW-Madison researchers were the original inventors of the TomoTherapy System, which Accuray now owns and develops.
The partnership focuses on three key areas: clinical research, education and training, and adaptive technology development. Online adaptive radiotherapy represents an important evolution in cancer treatment as it allows for real-time adjustments to radiation delivery based on daily changes in tumor position, size, and patient anatomy. This approach can potentially improve treatment precision while reducing side effects.
What makes this collaboration strategically valuable is the complementary expertise both parties bring. UW-Madison contributes deep academic research capabilities and clinical expertise, ranking
For Accuray shareholders, this partnership could accelerate innovation in a competitive radiation oncology market where precision and workflow efficiency are key differentiators. While this MOU represents an intent to collaborate rather than a binding agreement, it establishes a framework for knowledge exchange that could enhance Accuray's technological capabilities in the growing adaptive radiotherapy segment.
The timing is appropriate as radiation oncology continues shifting toward more personalized treatment approaches, with adaptive techniques gaining clinical acceptance. This collaboration allows Accuray to potentially strengthen its competitive position in this evolving landscape while building on its historical connection to the original TomoTherapy technology.
"I couldn't be prouder to announce this proposed collaboration with the University of
University of
"The origins of the TomoTherapy® System began right here at UW-Madison, and our clinical researchers have deep experience in bringing future innovations from bench to bedside," said Nita Ahuja, MD, MBA, Dean of the school and Vice Chancellor for Medical Affairs at the University of
About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases--while making commonly treatable cases even easier--to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in
About the University of Wisconsin School of Medicine and Public Health
The University of Wisconsin School of Medicine and Public Health is recognized as one of the nation's leading institutions in health sciences education, research, and service. Founded in 1907 as the medical school of the University of Wisconsin-Madison, in 2005 it became the nation's first school to integrate the disciplines of medicine and public health. With a deep commitment to a vision of healthy people and healthy communities, we translate discovery into application and interconnect clinical care, education and research. The school employs more than 5,600 faculty and staff and provides educational opportunities for nearly 3,000 students and postgraduate trainees. For federal fiscal year 2024, the school ranked #9 in the nation among public medical schools for NIH funding according to the Blue Ridge Institute for Medical Research. Some of the nation's leading researchers, educators, and clinicians are among the faculty, including several National Medal of Science recipients and National Academy of Science honorees.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to expectations related the proposed collaboration between the Company and the University of
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
Media Contacts
Beth Kaplan
Public Relations Director
Accuray
bkaplan@accuray.com
Robyn M. Perrin, Ph.D.
Chief Communications Officer
University of Wisconsin School of Medicine and Public Health
rmperrin@wisc.edu
View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-and-the-university-of-wisconsinmadison-announce-memorandum-of-understanding-to-advance-online-adaptive-radiotherapy-in-support-of-improving-cancer-patient-care-302570492.html
SOURCE Accuray Incorporated
FAQ
What is the significance of Accuray's partnership with University of Wisconsin-Madison?
How will this collaboration affect Accuray's (ARAY) market position in radiation therapy?
What is the current status of the Accuray-UW Madison partnership?
What are the main goals of Accuray's OART development program?
How does the TomoTherapy System improve cancer treatment?
